US 6,982,266 B2 | ||
Quinazoline derivatives as kinase inhibitors | ||
Anjali Pandey, Fremont, Calif. (US); Robert M. Scarborough, Half Moon Bay, Calif. (US); Kenji Matsuno, Tokyo (Japan); Michio Ichimura, Tokyo (Japan); Yuji Nomoto, Shizuoka (Japan); Shinichi Ide, Tokyo (Japan); Eiji Tsukuda, Tokyo (Japan); Junko Sasaki, Akita (Japan); and Shoji Oda, Tokyo (Japan) | ||
Assigned to Millennium Pharmaceuticals, Inc., Cambridge, Mass. (US); and Kyowa Hakko Kogyo Co., Ltd., Tokyo (Japan) | ||
Appl. No. 10/344,736 PCT Filed Aug. 17, 2001, PCT No. PCT/US01/41752 § 371(c)(1), (2), (4) Date Oct. 16, 2003, PCT Pub. No. WO02/16351, PCT Pub. Date Feb. 28, 2002. |
||
Claims priority of provisional application 60/226122, filed on Aug. 18, 2000. | ||
Prior Publication US 2005/0101609 A1, May 12, 2005 | ||
Int. Cl. A01K 31/675 (2006.01); A01K 31/517 (2006.01); C07D 43/02 (2006.01); C07D 239/72 (2006.01) |
U.S. Cl. 514—252.17 | 11 Claims |
1. A compound selected from the group consisting of: ![]() ![]() wherein R1 is a member selected from the group consisting of: CN, O-methyl, —O-ethyl, —O-propyl, —O-isopropyl, —O-butyl, —O-t-butyl,
—O-isoamyl, 1-naphthyloxy, 2-naphthyloxy, 4-indolyloxy, 5-indolyloxy, 5-isoquinolyloxy, and position isomers thereof;
n is 2 or 3;
R3 is a member selected from the group consisting of:
—OH, —O—CH3, —O—CH2—CH3, —NH2, —N(—CH3)2, —NH(—CH2-phenyl), —NH(-Phenyl), —CN
![]() and all pharmaceutically acceptable isomers, salts, hydrates, and solvates thereof.
|